Newron reports H1 2026 results; ENIGMA-TRS 1 nears target
Newron said ENIGMA-TRS 1 is nearing its ≥600-patient target (996 screened) and topline 12-week data are expected in Q1 2027. It also said U.S. enrollment in ENIGMA-TRS 2 is expected to resume after FDA clearance.
Newron reported H1 2026 results and said ENIGMA-TRS 1 is nearing its ≥600-patient target, with 996 screened and topline 12-week data expected in Q1 2027. S. Material DetailsContext by AI AnalystThis is mid-cycle: financial u…